4-aminobenzoyl-glycyl-prolyl-leucyl-alanine hydroxamic acid has been researched along with Atheroma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bliden, KP; Covic, L; Fletcher, EK; Gurbel, PA; Huang, T; Kimmelstiel, CD; Koukos, G; Kuliopulos, A; Rade, JJ; Rana, R; Shearer, A; Turner, SE | 1 |
1 other study(ies) available for 4-aminobenzoyl-glycyl-prolyl-leucyl-alanine hydroxamic acid and Atheroma
| Article | Year |
|---|---|
Noncanonical Matrix Metalloprotease 1-Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis.
Topics: Adult; Aged; Aged, 80 and over; Animals; Aortic Diseases; Atherosclerosis; Biomarkers; Carotid Artery Diseases; Cell Line; Cell-Penetrating Peptides; Clinical Trials, Phase II as Topic; Coronary Artery Disease; Disease Models, Animal; Disease Progression; Female; Fibrinolytic Agents; Human Umbilical Vein Endothelial Cells; Humans; Hydroxamic Acids; Lipopeptides; Male; Matrix Metalloproteinase 1; Matrix Metalloproteinase 13; Matrix Metalloproteinase Inhibitors; Mice, Inbred C57BL; Mice, Knockout, ApoE; Middle Aged; Multicenter Studies as Topic; Oligopeptides; Plaque, Atherosclerotic; Randomized Controlled Trials as Topic; Receptor, PAR-1; Signal Transduction; Tumor Necrosis Factor-alpha; United States | 2018 |